Logo image of ARGX.BR

ARGENX SE (ARGX.BR) Stock Fundamental Analysis

EBR:ARGX - Euronext Brussels - NL0010832176 - Common Stock - Currency: EUR

631.2  -0.2 (-0.03%)

Fundamental Rating

4

Taking everything into account, ARGX scores 4 out of 10 in our fundamental rating. ARGX was compared to 72 industry peers in the Biotechnology industry. ARGX scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. ARGX is valued quite expensively, but it does show have an excellent growth rating.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

ARGX had negative earnings in the past year.
ARGX had a negative operating cash flow in the past year.
ARGX had negative earnings in each of the past 5 years.
ARGX had negative operating cash flow in 4 of the past 5 years.
ARGX.BR Yearly Net Income VS EBIT VS OCF VS FCFARGX.BR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -200M -400M -600M -800M

1.2 Ratios

ARGX has a better Return On Assets (-5.77%) than 68.75% of its industry peers.
The Return On Equity of ARGX (-6.50%) is better than 71.88% of its industry peers.
Industry RankSector Rank
ROA -5.77%
ROE -6.5%
ROIC N/A
ROA(3y)-14.49%
ROA(5y)-16.28%
ROE(3y)-16.18%
ROE(5y)-20.05%
ROIC(3y)N/A
ROIC(5y)N/A
ARGX.BR Yearly ROA, ROE, ROICARGX.BR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 -10 -20 -30 -40

1.3 Margins

With an excellent Gross Margin value of 89.36%, ARGX belongs to the best of the industry, outperforming 85.94% of the companies in the same industry.
ARGX does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 89.36%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ARGX.BR Yearly Profit, Operating, Gross MarginsARGX.BR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -500 -1K

More info and screens

6

2. Health

2.1 Basic Checks

ARGX does not have a ROIC to compare to the WACC, probably because it is not profitable.
ARGX has more shares outstanding than it did 1 year ago.
The number of shares outstanding for ARGX has been increased compared to 5 years ago.
The debt/assets ratio for ARGX is higher compared to a year ago.
ARGX.BR Yearly Shares OutstandingARGX.BR Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M 40M 50M
ARGX.BR Yearly Total Debt VS Total AssetsARGX.BR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 1B 2B 3B 4B

2.2 Solvency

ARGX has an Altman-Z score of 44.39. This indicates that ARGX is financially healthy and has little risk of bankruptcy at the moment.
The Altman-Z score of ARGX (44.39) is better than 96.88% of its industry peers.
ARGX has a Debt/Equity ratio of 0.01. This is a healthy value indicating a solid balance between debt and equity.
ARGX has a better Debt to Equity ratio (0.01) than 85.94% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF N/A
Altman-Z 44.39
ROIC/WACCN/A
WACC7.08%
ARGX.BR Yearly LT Debt VS Equity VS FCFARGX.BR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 1B 2B 3B 4B

2.3 Liquidity

ARGX has a Current Ratio of 8.53. This indicates that ARGX is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of ARGX (8.53) is better than 92.19% of its industry peers.
A Quick Ratio of 7.88 indicates that ARGX has no problem at all paying its short term obligations.
With an excellent Quick ratio value of 7.88, ARGX belongs to the best of the industry, outperforming 90.63% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 8.53
Quick Ratio 7.88
ARGX.BR Yearly Current Assets VS Current LiabilitesARGX.BR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 1B 2B 3B 4B

More info and screens

7

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 78.85% over the past year.
Looking at the last year, ARGX shows a very strong growth in Revenue. The Revenue has grown by 62.02%.
ARGX shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 120.70% yearly.
EPS 1Y (TTM)78.85%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%211.2%
Revenue 1Y (TTM)62.02%
Revenue growth 3Y209.8%
Revenue growth 5Y120.7%
Sales Q2Q%73.28%

3.2 Future

The Earnings Per Share is expected to grow by 51.67% on average over the next years. This is a very strong growth
ARGX is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 36.83% yearly.
EPS Next Y127.93%
EPS Next 2Y99.71%
EPS Next 3Y78.55%
EPS Next 5Y51.67%
Revenue Next Year76.75%
Revenue Next 2Y65.66%
Revenue Next 3Y54.22%
Revenue Next 5Y36.83%

3.3 Evolution

The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
ARGX.BR Yearly Revenue VS EstimatesARGX.BR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 2B 4B 6B 8B
ARGX.BR Yearly EPS VS EstimatesARGX.BR Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 20 40 60

More info and screens

3

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ARGX. In the last year negative earnings were reported.
The Price/Forward Earnings ratio is 63.83, which means the current valuation is very expensive for ARGX.
Compared to the rest of the industry, the Price/Forward Earnings ratio of ARGX indicates a somewhat cheap valuation: ARGX is cheaper than 79.69% of the companies listed in the same industry.
When comparing the Price/Forward Earnings ratio of ARGX to the average of the S&P500 Index (92.74), we can say ARGX is valued slightly cheaper.
Industry RankSector Rank
PE N/A
Fwd PE 63.83
ARGX.BR Price Earnings VS Forward Price EarningsARGX.BR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 -200 -400 -600

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ARGX.BR Per share dataARGX.BR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 20 40 60

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as ARGX's earnings are expected to grow with 78.55% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y99.71%
EPS Next 3Y78.55%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ARGX!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ARGENX SE

EBR:ARGX (2/5/2025, 11:24:04 AM)

631.2

-0.2 (-0.03%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)10-31 2024-10-31/bmo
Earnings (Next)02-27 2025-02-27/amc
Inst Owners39.77%
Inst Owner ChangeN/A
Ins Owners0.12%
Ins Owner ChangeN/A
Market Cap37.74B
Analysts81.67
Price Target648.61 (2.76%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)59.25%
Min EPS beat(2)-26.77%
Max EPS beat(2)145.26%
EPS beat(4)2
Avg EPS beat(4)31.06%
Min EPS beat(4)-26.77%
Max EPS beat(4)145.26%
EPS beat(8)5
Avg EPS beat(8)33.89%
EPS beat(12)9
Avg EPS beat(12)29.37%
EPS beat(16)11
Avg EPS beat(16)35.2%
Revenue beat(2)1
Avg Revenue beat(2)4.46%
Min Revenue beat(2)-0.25%
Max Revenue beat(2)9.17%
Revenue beat(4)3
Avg Revenue beat(4)6.89%
Min Revenue beat(4)-0.25%
Max Revenue beat(4)11.26%
Revenue beat(8)7
Avg Revenue beat(8)18.48%
Revenue beat(12)10
Avg Revenue beat(12)21.7%
Revenue beat(16)12
Avg Revenue beat(16)37.73%
PT rev (1m)8.52%
PT rev (3m)22.4%
EPS NQ rev (1m)0%
EPS NQ rev (3m)364.4%
EPS NY rev (1m)283.1%
EPS NY rev (3m)244.61%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0.09%
Revenue NY rev (1m)6.91%
Revenue NY rev (3m)7.33%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 63.83
P/S 20.05
P/FCF N/A
P/OCF N/A
P/B 9.15
P/tB 9.47
EV/EBITDA N/A
EPS(TTM)-0.85
EYN/A
EPS(NY)9.89
Fwd EY1.57%
FCF(TTM)-5.26
FCFYN/A
OCF(TTM)-4.2
OCFYN/A
SpS31.47
BVpS68.97
TBVpS66.67
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -5.77%
ROE -6.5%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 89.36%
FCFM N/A
ROA(3y)-14.49%
ROA(5y)-16.28%
ROE(3y)-16.18%
ROE(5y)-20.05%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.41
Health
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 56%
Cap/Sales 3.37%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 8.53
Quick Ratio 7.88
Altman-Z 44.39
F-Score4
WACC7.08%
ROIC/WACCN/A
Cap/Depr(3y)736.22%
Cap/Depr(5y)853.41%
Cap/Sales(3y)17.76%
Cap/Sales(5y)25.06%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)78.85%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%211.2%
EPS Next Y127.93%
EPS Next 2Y99.71%
EPS Next 3Y78.55%
EPS Next 5Y51.67%
Revenue 1Y (TTM)62.02%
Revenue growth 3Y209.8%
Revenue growth 5Y120.7%
Sales Q2Q%73.28%
Revenue Next Year76.75%
Revenue Next 2Y65.66%
Revenue Next 3Y54.22%
Revenue Next 5Y36.83%
EBIT growth 1Y48.44%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year70.23%
EBIT Next 3Y75.76%
EBIT Next 5Y55.78%
FCF growth 1Y62.81%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y70.38%
OCF growth 3YN/A
OCF growth 5YN/A